Filing Flows

Filing Flows › Sensus Healthcare (SRTS) › Q3 2025

Sensus Healthcare (SRTS) Q3 2025 earnings results (third quarter 2025)

10-Q filed Nov 12, 2025

Sensus Healthcare (SRTS) reported revenue of $6.9M for the third quarter 2025 (Q3 2025), -22% from a year earlier and -6% from the quarter before. Operating margin was -37.3%, net loss $943K (13.7% of revenue).

Revenue$6.9M
Year over year-22%
Quarter over quarter-6%
Operating margin-37.3%
Net earnings−$943K

Sensus Healthcare, Q3 2025: revenue $6.9M (-22% year over year), operating margin -37.3%, net loss $943K, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.

Q3 2025AmountQ/QY/Y
Revenue$6.9M-6%-22%
Operating profit−$2.6M——
Net earnings−$943K——
Operating cash flow$2.3M-26%-42%
Free cash flow$2.3M-26%-37%

What changed

Revenue was $6.9M in Q3 2025, down 22% year over year and down 6% from the previous quarter. Product was the largest line at 70% of revenue. Product lost $2.6M year over year (down 35%), 135% of the total change.

Gross margin was 39.4%, down 19.9 points from a year earlier. Operating costs exceeded revenue by $2.6M, an operating margin of -37.3%. Operating expenses grew 41% against a revenue fall of 22%. The fastest-growing cost line was Research & development (+111%). The quarter ended with a net loss of $943K, narrower than the previous quarter's $1.0M loss.

Operating cash flow was $2.3M (down 42% year over year). Non-cash charges added back $98K of depreciation and $73K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $4K left free cash flow of $2.3M.

Questions

What was Sensus Healthcare's revenue in the third quarter 2025?

Sensus Healthcare (SRTS) reported revenue of $6.9M for the third quarter 2025 (Q3 2025), -22% from a year earlier and -6% from the quarter before.

Was Sensus Healthcare profitable in the third quarter 2025?

Operating loss was $2.6M (-37.3% of revenue) and net loss $943K.

Open the interactive Sankey →

Source: Sensus Healthcare 10-Q on SEC EDGAR.